SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of these patients by developing durable drug delivery solutions that empower both patients and surgeons with confidence in long-term disease control and vision preservation. Headquartered in Aliso Viejo, California, SpyGlass Pharma was incorporated in Delaware in January 2019.

SpyGlass Pharma's lead product candidate is the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This system integrates novel, proprietary drug pads with an intraocular lens (IOL) designed for implantation during routine cataract surgery. Its purpose is to reduce elevated intraocular pressure (IOP) in patients suffering from open-angle glaucoma (OAG) or ocular hypertension (OHT) by consistently delivering bimatoprost for up to three years. The company is also developing the BIM-DRS (Drug Ring System), a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost, intended for standalone implantation or retreatment for patients not undergoing cataract surgery.

SpyGlass Pharma completed its Initial Public Offering (IPO) on Nasdaq, with its common stock trading under the ticker symbol "SGP" starting February 6, 2026, raising $172.5 million. In March 2026, the company announced positive topline 12-month data from its Phase 1/2 trial for the BIM-IOL System, demonstrating significant IOP reduction and a high percentage of patients free from topical medications. Led by CEO Patrick Mooney and co-founded by Malik Y. Kahook, M.D., and Glenn Sussman, the company initiated two registrational Phase 3 clinical trials for the BIM-IOL System in July 2025, aiming to address unmet needs in long-term therapeutic durability and patient adherence in the glaucoma market.